Johnson & Johnson Pharmaceutical Research & Development, LLC (CA) Release: Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Progra

SAN FRANCISCO--(BUSINESS WIRE)--Results from a pre-specified pooled analysis of the RECORD clinical trial program showed that the novel, investigational, oral anticoagulant rivaroxaban was superior to enoxaparin treatment regimens for the prevention of venous thromboembolism (VTE) after total knee or hip replacement surgery. The data also show that rates of major bleeding were low and not statistically different from the comparator.